



Press Release

Metabrain Research and ImaBiotech initiate a strategic partnership to offer cutting-edge preclinical research services in metabolic disorders.

Lille, 17th January 2019 – Metabrain Research and ImaBiotech have announced the launch of a new preclinical service for Biotech-Pharma-MedTech companies allowing the measurement of tissue distribution, pharmacokinetic and pharmacodynamic (PK/PD) drug effects in preclinical metabolic disorders models.

This innovative joint offer will combine ImaBiotech's state of the art platforms in bioanalysis to measure and confirm the efficacy of a drug at the cellular level and Metabrain Research's mastery to develop new molecules in metabolic age-related diseases such as NASH, diabetes, sarcopenia and related immuno-inflammatory disorders.

Dr. David Bonnel, Executive Director at ImaBiotech (France), commented, "ImaBiotech is proud to extend its preclinical research services with this new partnership dedicated to metabolic disorders. Metabrain Research has developed this past decade an impressive expertise in this therapeutic area based on specific diseases models. The combination of our platforms will reinforce our capabilities and the possibility for our sponsors to evaluate their drug mechanism of action and efficacy in this therapeutic field from early to late stages."

Dr. Valérie Autier, CEO of Metabrain Research, added, "We act daily, to better characterize the mechanism and the site of action of drugs. We've been very impressed by the precision and the potency of Imabiotech's technology. Through this new combination of expertise, our clients will gain access to the most powerful tool dedicated to the hit and lead selection and their optimization into preclinical candidates.

About Metabrain Research:

Metabrain is a biopharmaceutical company developing innovation for Human Health Industry, created in 2009, located in Maisons-Alfort (Paris area, France), recognized as one of the main players in the field of personalized medicine for metabolic aging. Metabrain is building up the next generation of Partnering Research Organization to promote early stage innovation at industrial standards, offering translational R&D capacities combining patient data, AI-based biomarkers and exclusive pathological models which recapitulate most of the human disease

hallmarks and their age-related complications.

To learn more about Metabrain Research:

- Alexandre Labe – Head of Marketing & Partnership Manager
- a.labe@metabrainresearch.com - +33 (0) 669 257 102
- www.metabrainresearch.com

About ImaBiotech:

ImaBiotech is a Contract Research Organization (CRO) with facilities in Boston (MA, USA) and Lille (Eurasanté Parc, France). The company offers innovative services and software to the pharmaceutical research sector, providing highly *in vivo* informative drug efficacy and toxicity evaluations during preclinical and clinical stage developments at cellular level, making better and safer drugs.

Services are based on histology combined to label free molecular imaging (Quantitative Mass Spectrometry Imaging, QMSI) a technology developed and constantly improved by ImaBiotech. QMSI is a game changer for the pharmaceutical industry in all therapeutic areas. While other techniques provide global information, this molecular technique provides a deeper understanding of a drugs localization and its pharmacological effects at cellular level. This improves the interpretation of drug efficacy and toxicity, resulting in better drugs and decreasing time-to-market.

To learn more about ImaBiotech:

- Edma Fontaine – Communication and Marketing Manager
- fontaine.edma@imabiotech.com - +33 (0) 374 095 546
- www.ImaBiotech.com